Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

NUZ commences its most important chapter yet

Neurizon Therapeutics
3:27pm
February 26, 2026
NUZ has dosed the first patient in the HEALEY ALS Platform Trial, marking the shift from early proof of concept into a potentially pivotal clinical program. This represents a key milestone for the company and sets the stage for a more meaningful period of clinical news flow into 2H CY26 when enrolment is expected to complete. No changes to forecasts and maintain our SPECULATIVE BUY rating, noting the high risk / high reward proposition.

1H26 result: Improving optics into 2H and beyond

Microba Life Sciences
3:27pm
February 26, 2026
A comfortable result and well flagged in the recent 2Q26 report. Result soft on legacy roll off, but core testing remains strong with volumes up 113% and Explorer lifting to 55% of revenue. Cost base reset on track with underlying loss improving YoY, leaving MAP well positioned for a cleaner 2H with improving leverage and clearer revenue optics. Minor changes to forecasts and no change to target price of A$0.29 p/s. Retain Speculative Buy recommendation.

1H26 result: Plenty of cash, not enough spark

Clinuvel Pharmaceuticals
3:27pm
February 26, 2026
CUV delivered a softer result that landed below expectations, with top line underperformance and operational cost growth materially outpacing revenue. The combination of slower revenue growth, heavier opex, FX drag, and margin compression makes for an underwhelming print relative to expectations. While fundamentally cheap with a large cash balance providing valuation support and trading well below historical multiples, the outlook continues to hinge on clinical catalysts and a change in sentiment (strategic direction driven) which we view is unlikely to shift meaningfully in the near term. Minor downgrades due to higher OpEx base and adjustments to WACC. Our target price reduces to A$13 (from A$14) but retain a SPECULATIVE BUY recommendation.

Ravensthorpe a Go

Medallion Metals
3:27pm
February 26, 2026
We update our coverage of MM8 to incorporate the recently released Feasibility Study and positive EPBC permitting, outlining integration of the Forrestania processing infrastructure with the 1.2Moz AuEq Ravensthorpe Gold Project. MM8 is now fully funded, supported by a US$50m offtake-linked financing facility with commodity trader Trafigura, removing a key development overhang. We see strong parallels with covered stock ASX.MEK, where leveraging existing processing infrastructure drove a similar scale production profile and translated into outsized shareholder returns through the development phase. We maintain our SPECULATIVE BUY rating, with a price target of A$0.87ps (previously A$0.61ps).

1H26 result: International momentum building

Jumbo Interactive
3:27pm
February 26, 2026
Jumbo Interactive (JIN) reported a solid 1H26 result, with most headline metrics pre-released. While Lottery Retailing was impacted by a softer jackpot cycle, offshore segments delivered encouraging growth and margin expansion. Managed Services continues to build momentum, with Canada EBITDA guidance upgraded and the UK tracking nicely. Underlying SaaS trends remain healthy ex-Lotterywest. Following the update, we believe JIN can delever by FY27F, assuming a normalisation in Australian jackpot activity and continued offshore earnings growth. We have updated our model to reflect upgraded Managed Services and Prize Draw guidance, alongside refreshed FX assumptions. Our underlying EBITDA increases +1%/+5% across FY26-27F. We maintain our BUY recommendation with an unchanged $14.90 target price.

1H26 Result: Operational leverage drives earnings

Wagners
3:27pm
February 26, 2026
WGN delivered an exceptional set of results, with 1H26 EBIT beating guidance (+9.5%), our expectations (+8.4%) and consensus (+10.6%). Full year guidance was materially upgraded, with the implied 2H26 EBIT of $27-$31m a 32% beat vs prior guidance and consensus, as strong demand continues across construction materials, while CFT poles are on track to triple (vs FY25). The balance sheet is also now net cash, with the business well positioned to execute on its capex plans and capture continued demand for cement/concrete in South-East Queensland, along with CFT demand. This positive view sees us upgrade to a Buy recommendation with a $5.00/sh price target.

1H26 result: A small step and a giant leap

WiseTech Global
3:27pm
February 25, 2026
WTC’s 1H26 result was a modest beat to MorgF/Consensus with Revenue of US$672m (~2% ahead MorgF/consensus), Underlying EBITDA was US$252.1m (margins of 38%) and Underlying NPATA was US$114m, ~3% ahead of consensus of US$111.0m. FY26 guidance was reiterated, however the next phase of WTC’s Ai-led transformation came as a surprise with the group targeting a material head count reduction over FY26/FY27 as it leans into companywide Ai adoption to drive cost and workflow efficiencies on the path to a return to 50% EBITDA margins. Updating our numbers to reflect WTC’s 1H26 result and FY26 outlook sees our revenue and EBITDA forecasts revised lower by ~1-3% in FY26-FY28F. Our DCF/EV/EBITDA based price target is revised to A$83.60ps (from A$112.50ps), with our BUY rating retained.

FY25 result: Not standing idle

IRESS
3:27pm
February 25, 2026
IRE delivered a solid FY25 result with underlying EBITDA of A$136.2m, +4.7% ahead of our estimate, and the group’s FY25 guidance range. Divisionally each segment delivered solid EBITDA growth half on half, with APAC Wealth up +24.5%, UK Wealth +46%, and GTMD +8.6%. FY26 Cash EBITDA guidance (underlying EBITDA less capex) was provided at A$116-126m (representing 15-26% growth YoY). IRE flagged that capex for FY26 will remain in line with FY25, which implies further operating leverage is expected. We upgrade our underlying EBITDA forecasts by +5-6%, which sees our price target increase to $10.95 from $10.50. With over 50% implied TSR, we move to a BUY rating from ACCUMULATE.

1H26 result: Strategy translating into results

Tabcorp Holdings
3:27pm
February 25, 2026
Tabcorp Holdings (TAH) reported a very strong 1H26 result, with resilient turnover, improved margins and disciplined cost control driving double-digit EBITDA growth despite a softer wagering yield environment through the Spring Carnival and Footy Finals period. New and exclusive products resonated well, particularly with younger cohorts, with digital turnover among 18-24 year olds up +14%. Following the result, our EPS estimates increase +9%/+12% across FY26-27F, reflecting stronger Wagering & Media margins and sustained operating leverage. We maintain our Accumulate recommendation, while our target price increases to $1.20 (previously $1.07).

Corporate shines, Leisure is better than feared

Flight Centre Travel
3:27pm
February 25, 2026
FLT’s 1H26 NBPT was up 4.1%, a beat on guidance for a flat result. The Corporate result was the highlight with NPBT was up 20%, while Leisure was better than feared down only 4%. The 3Q26 is off to a strong start and importantly Leisure is back in growth. FY26 guidance was reiterated. We have made minor upgrades to our forecasts. FLT’s fundamentals remain attractive (FY27 PE of 10.6x) and we retain a Buy recommendation with a new A$18.05 price target.

News & insights

Kevin Warsh outlines a bottom-up restructuring of the Federal Reserve, introducing five task forces and reshaping how the Fed approaches communication, data, and inflation.
Read more
Why does the RBA look set to hike rates to 4.85% even as oil prices fall? It's not what the Treasurer says. We explain what's really driving inflation.
Read more
Your Wealth covers EOFY super tips, CGT reform impacts, the 2026 Federal Budget, franking credit changes, and Division 296, essential reading for investors.
Read more